论文部分内容阅读
目的 探索幽门螺杆菌 (Hp)与反流性食管炎的相关性。方法 对确诊的 43例反流性食管炎及同期条件相匹配的5 0例慢性胃炎及 47例十二指肠溃疡患者采用日产PQ2 0型 0Lympus纤维胃镜检查并取胃粘膜四块用Hp检测试纸行快速尿素酶测定 ,同时取空腹静脉血用ELISA方法测定血Hp -IgG抗体。Hp阴性的反流性食管炎患者 (15例 )分为A、B两组 :A组 (n =7)接受法莫替丁 (2 0mg ,Bid)治疗 ,B组 (n =8)接受法莫替丁 (2 0mg ,Bid)及西沙比利 (10mg ,Tid) ,各治疗 2 8天。Hp阳性反流性食管炎患者 (2 8例 )分为C、D两组 :C组 (n =14 )接受洛赛克 (2 0mg ,Bid)及西沙比利 (10mg ,Tid)治疗 ,D组 (n =14 )接受洛赛克 (2 0mg ,Bid)、羟氨苄青霉素 (0 5 ,Tid)、呋喃唑酮 (0 2 ,Tid)及西沙比利 (10mg ,Tid)治疗 ,各治疗 14天。结果 1、Hp在反流性食管炎、慢性胃炎、十二指肠溃疡的检出率分别为 65 1%、64 %及 80 8% (P >0 .0 5 )。 2、Ⅰ、Ⅱ、Ⅲ及Ⅳ级食管炎的百分率分别为 3 0 2 %、46 5 %、18 6%及 4 7%。无Ⅴ级食管炎。各级食管炎患者Hp检出率分别为 61 5 %、5 5 %、87 5 %及 10 0 % (P >0 .0 5 )。 3、A、B组治疗显效率 (反流症状消失 )为5 7 1%及 10 0 % (P <0 .0 5 )。C、D组治疗显效率为 64 3 %及 92 9% (P >0
Objective To explore the correlation between Helicobacter pylori (Hp) and reflux esophagitis. Methods Forty-three cases of reflux esophagitis and 50 cases of chronic gastritis and 47 cases of duodenal ulcer which matched with the same period were diagnosed by gastroscopy with Nissl PQ20 type 0Lympus and gastric mucosa were taken with Hp test strip Fast urease determination of fasting venous blood at the same time with ELISA method for determination of blood Hp-IgG antibody. Hp-negative patients with reflux esophagitis (15 cases) were divided into two groups: group A (n = 7) received famotidine (20 mg) and group B (n = 8) (20mg, Bid) and cisapride (10mg, Tid), each treatment 28 days. Hp positive reflux esophagitis patients (28 cases) were divided into C and D groups: C group (n = 14) received Losec (20 mg, Bid) and cisapride (10 mg, Tid) The patients were treated with Losec (20 mg, Bid), amoxicillin (0 5, Tid), furazolidone (0 2, Tid) and cisapride (10 mg, Tid) for 14 days. Results 1. The detection rates of Hp in reflux esophagitis, chronic gastritis and duodenal ulcer were 65 1%, 64% and 80 8% respectively (P 0. 05). 2, Grade I, II, III and IV esophagitis were respectively 302%, 465%, 18 6% and 47%. No grade â ... esophagitis. The detection rate of Hp in patients with esophagitis was 61.5%, 55%, 87.5% and 100% respectively (P> 0.05). The effective rate of treatment in Group A and B (disappearance of reflux symptoms) was 57.1% and 100% respectively (P <0.05). The effective rates of treatment in groups C and D were 64.3% and 92.9%, respectively (P> 0